Research > ETFs > ETF / ETP Commentary > 

China ETFs’ Paradox: Winning But Ignored in 2025 

It’s been a good year for international equity ETFs. As a category, broad exposure funds tapping into both developed and emerging market equities have delivered outsized gains relative to U.S. markets this year, as well as much sought portfolio diversification. Consider two popular ETF examples. The iShares Core MSCI Emerging Markets ETF (IEMG A) and the Vanguard FTSE Europe ETF (VGK A) have both outpaced the SPDR S&P 500 (SPY A-) in 2025. One of them has delivered more than twice the results of SPY, as seen in table below. Investors have taken notice. IEMG has picked up more than $11.4 billion in fresh net assets this year. Meanwhile, VGK has seen $6.2 billion in net inflows. Other broad-based international equity ETFs benefiting from this momentum include:  Vanguard Total International Stock ETF (VXUS A) +$14.6 billion  Vanguard FTSE Developed Markets ETF (VEA A-) +$12.4 billion iShares Core MSCI EAFE ETF (IEFA A) +$8.9 billion Avantis Emerging Markets Equity ETF (AVEM ) +$4.3 billion iShares MSCI Intl Quality Factor ETF (IQLT A-) +$3.7 billion Dimensional International Value ETF (DFIV A+) +$3.2 billion What’s been interesting to note, however, is that appetite for international equity exposure and diversification has largely stayed top level. It hasn’t spilled much into single country opportunities. Case in point: China. Broad-based China ETFs out of Favor China has made a lot of headlines this year. From trade and tariff disputes with the U.S. to concerns about economic momentum to uncertainty as a new Five Year Plan takes shape for 2026, China has been at the center of a lot of noise.    And yet, China equities have been delivering strong results, outpacing U.S. markets notably in 2025. According to Jeff Weniger, head of equity strategy at WisdomTree, China has been standing out all year, but no one seems to really care. In fact, he calls China an “amazing contrarian” opportunity for investors ready to buck the noise. WisdomTree is behind the WisdomTree China ex-State Owned Enterprises Fund (CXSE A-).  “China [CXSE] is one of the best performing funds we have this year. It’s most people’s best performing fund this year and the grand total sum of interest I’m seeing from advisors is zero,” Weniger said in a recent webcast conversation. “I’ve never seen such a thing where you reach Halloween, and your best performing fund has no interest at all.”  “China has been going up on account of the ‘TINA’ trade, where you have a 5-Year Sovereign at 1.62% or you can own tech stocks, and people have gone for the tech stocks.” CXSE is up more than 40% in 2025. That’s about 10 percentage points higher than the results seen in the iShares China Large-Cap ETF (FXI A) — a popular proxy for the category — itself up more than 30%. Demand has been nowhere to be found. In fact, investors have pulled money from CXSE this year. FXI has bled more than $2 billion in net redemptions. Another popular China ETF, the mainland-China-focused Xtrackers Harvest CSI 300 China A-Shares ETF (ASHR B+), too, has seen $1.4 billion in net outflows.  China Tech? Yes, PleaseOne of the exceptions to this shunning of China-focused ETFs is the tech space. China tech ETFs have been capturing fresh attention, riding the appetite for all things tech we continue to see globally.  Funds like the KraneShares CSI China Internet ETF (KWEB B), which is up 36% this year, has taken in $2.2 billion in net inflows. The Invesco China Technology ETF (CQQQ B-), up 44% year-to-date, has picked up $2 billion. These ETFs offer access to some of the most popular China tech stocks like Tencent, Meituan, Alibaba, Baidu and JD.com, among others.  As we navigate the fourth quarter and revisit portfolio allocations for a new calendar year, winners and losers will come into sharp focus. Calls for continued focus on the international equity opportunity remain loud, but China ETFs sit at an interesting place, delivering solid gains to very little investor fanfare. It will be interesting to see what happens next.  For a replay of WisdomTree’s webcast “Unlocking Opportunities in the U.S. and Beyond” Weniger’s comments, check out this link. This article was prepared as part of WisdomTree’s general paid sponsorship of VettaFi | ETF Trends. This specific content within and any opinions expressed therein belong solely to VettaFi and do not reflect the opinion or analysis of WisdomTree, its employees, or its affiliates. Content published on VettaFi | ETF Trends is provided for educational purposes only and should not be considered investment or tax advice. For investment or tax advice, please consult a financial professional.  WisdomTree is an independent company, unaffiliated with VettaFi | ETF Trends. WisdomTree has not been involved with the preparation of the content supplied by VettaFi | ETF Trends. It does not guarantee, or assume any responsibility for its content. For more news, information, and analysis, visit the Modern Alpha Content Hub.

Performance data shown is past performance and is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore you have a gain or loss when you sell your shares. For standard quarterly performance, go to the fund's Snapshot page by clicking on the ETF/ETP's symbol.

ETFs may trade at a premium or discount to their NAV and are subject to the market fluctuations of their underlying investments.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF's prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock, Inc. and its affiliates.

FBS receives compensation from the fund's advisor or its affiliates in connection with a marketing program that includes the promotion of this security and other ETFs to customers ("Marketing Program"). The Marketing Program creates incentives for FBS to encourage the purchase of certain ETFs. Additional information about the sources, amounts, and terms of compensation is in the ETF's prospectus and related documents. Please note that this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral.

News, commentary (including "Related Symbols") and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.